Editorial: One small step for metaplasia, but one giant leap for biomarkers is needed

6Citations
Citations of this article
11Readers
Mendeley users who have this article in their library.

Abstract

There are 5 to 6 levels of biomarker validation. Those for Barrett's esophagus are currently at level 3, despite small prospective studies. What is ideally required is a very large prospective assessment of biopsies in large cohorts, such as the ASPirin Esomeprazole Chemoprevention Trial (AspECT) and Barrett's Oesophagus Surveillance Study (BOSS) trials, so that unbiased and random selection of cases can be subjected to rigorous pathology and biomarker assessment (level 4). Only then can the predictive power of the data be exploited in a randomized intervention trial (level 5) whereby a series of biomarkers would trigger therapy. The real trouble is that this spot is currently occupied, satisfactorily according to some researchers, by conventional histological identification of high-grade dysplasia (HGD) as used in a recent randomized study of ablation in Barrett's esophagus (BE). © 2009 by the American College of Gastroenterology.

Cite

CITATION STYLE

APA

Nicholson, A., & Jankowski, J. (2009, November). Editorial: One small step for metaplasia, but one giant leap for biomarkers is needed. American Journal of Gastroenterology. https://doi.org/10.1038/ajg.2009.450

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free